Abhinav Sharma1,2,3, Xin Zhao4, Bradley G Hammill4, Adrian F Hernandez4, Gregg C Fonarow5, G Michael Felker4, Clyde W Yancy6, Paul A Heidenreich7, Justin A Ezekowitz2, Adam D DeVore4. 1. Duke Clinical Research Institute, Duke University, Durham, NC (A.S., X.Z., B.G.H., A.F.H., G.M.F., A.D.D.). a.sharma@duke.edu. 2. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada (A.S., J.A.E.). 3. Division of Cardiology, Stanford University, Palo Alto, CA (A.S.). 4. Duke Clinical Research Institute, Duke University, Durham, NC (A.S., X.Z., B.G.H., A.F.H., G.M.F., A.D.D.). 5. The Ahmanson-University of California Los Angeles Cardiomyopathy Centre, Ronald Regan University of California Los Angeles Medical Centre (G.C.F.). 6. Feinberg School of Medicine, Northwestern University, Chicago, IL (C.W.Y.). 7. Veterans' Affairs, Palo Alto Health Care System, CA (P.A.H.).
Abstract
BACKGROUND: The increase in medical complexity among patients hospitalized with heart failure (HF) may be reflected by an increase in concomitant noncardiovascular comorbidities. Among patients hospitalized with HF, the temporal trends in the prevalence of noncardiovascular comorbidities have not been well described. METHODS AND RESULTS: We used data from 207 984 patients in the Get With The Guidelines-Heart Failure registry (from 2005 to 2014) to evaluate the prevalence and trends of noncardiovascular comorbidities (chronic obstructive pulmonary disorder/asthma, anemia, diabetes mellitus, obesity [body mass index ≥30 kg/m2], and renal impairment) among patients hospitalized with HF. Medicare beneficiaries aged ≥65 years were used to assess 30-day mortality. The prevalence of 0, 1, 2, and ≥3 noncardiovascular comorbidities was 18%, 30%, 27%, 25%, respectively. From 2005 to 2014, there was a decline in patients with 0 noncardiovascular comorbidities (22%-16%; P<0.0001) and an increase in patients with ≥3 noncardiovascular comorbidities (18%-29%; P<0.0001). Among Medicare beneficiaries, there was an increased 30-day adjusted mortality risk among patients with 1 noncardiovascular comorbidity (hazard ratio, 1.16; 95% confidence interval, 1.09-1.24; P<0.0001), 2 noncardiovascular comorbidities (hazard ratio, 1.34; 95% confidence interval, 1.25-1.44; P<0.0001), and ≥3 noncardiovascular comorbidities (hazard ratio, 1.63; 95% confidence interval, 1.51-1.75; P<0.0001). Similar trends were seen for in-hospital mortality. CONCLUSIONS: Patients admitted in hospital for HF have an increasing number of noncardiovascular comorbidities over time, which are associated with worse outcomes. Strategies addressing the growing burden of noncardiovascular comorbidities may represent an avenue to improve outcomes and should be included in the delivery of in-hospital HF care.
BACKGROUND: The increase in medical complexity among patients hospitalized with heart failure (HF) may be reflected by an increase in concomitant noncardiovascular comorbidities. Among patients hospitalized with HF, the temporal trends in the prevalence of noncardiovascular comorbidities have not been well described. METHODS AND RESULTS: We used data from 207 984 patients in the Get With The Guidelines-Heart Failure registry (from 2005 to 2014) to evaluate the prevalence and trends of noncardiovascular comorbidities (chronic obstructive pulmonary disorder/asthma, anemia, diabetes mellitus, obesity [body mass index ≥30 kg/m2], and renal impairment) among patients hospitalized with HF. Medicare beneficiaries aged ≥65 years were used to assess 30-day mortality. The prevalence of 0, 1, 2, and ≥3 noncardiovascular comorbidities was 18%, 30%, 27%, 25%, respectively. From 2005 to 2014, there was a decline in patients with 0 noncardiovascular comorbidities (22%-16%; P<0.0001) and an increase in patients with ≥3 noncardiovascular comorbidities (18%-29%; P<0.0001). Among Medicare beneficiaries, there was an increased 30-day adjusted mortality risk among patients with 1 noncardiovascular comorbidity (hazard ratio, 1.16; 95% confidence interval, 1.09-1.24; P<0.0001), 2 noncardiovascular comorbidities (hazard ratio, 1.34; 95% confidence interval, 1.25-1.44; P<0.0001), and ≥3 noncardiovascular comorbidities (hazard ratio, 1.63; 95% confidence interval, 1.51-1.75; P<0.0001). Similar trends were seen for in-hospital mortality. CONCLUSIONS:Patients admitted in hospital for HF have an increasing number of noncardiovascular comorbidities over time, which are associated with worse outcomes. Strategies addressing the growing burden of noncardiovascular comorbidities may represent an avenue to improve outcomes and should be included in the delivery of in-hospital HF care.
Authors: Ambarish Pandey; Muthiah Vaduganathan; Sameer Arora; Arman Qamar; Robert J Mentz; Sanjiv J Shah; Patricia P Chang; Stuart D Russell; Wayne D Rosamond; Melissa C Caughey Journal: Circulation Date: 2020-06-03 Impact factor: 29.690
Authors: Ankeet S Bhatt; Andrew P Ambrosy; Allison Dunning; Adam D DeVore; Javed Butler; Shelby Reed; Adriaan Voors; Randall Starling; Paul W Armstrong; Justin A Ezekowitz; Marco Metra; Adrian F Hernandez; Christopher M O'Connor; Robert J Mentz Journal: Eur J Heart Fail Date: 2020-03-25 Impact factor: 15.534
Authors: Boback Ziaeian; Adrian F Hernandez; Adam D DeVore; Jingjing Wu; Haolin Xu; Paul A Heidenreich; Roland A Matsouaka; Deepak L Bhatt; Clyde W Yancy; Gregg C Fonarow Journal: Am Heart J Date: 2019-01-27 Impact factor: 4.749
Authors: Melissa C Caughey; Muthiah Vaduganathan; Sameer Arora; Arman Qamar; Robert J Mentz; Patricia P Chang; Clyde W Yancy; Stuart D Russell; Sanjiv J Shah; Wayne D Rosamond; Ambarish Pandey Journal: J Am Geriatr Soc Date: 2021-01-05 Impact factor: 5.562
Authors: P Elliott Miller; Alexander Thomas; Thomas J Breen; Fouad Chouairi; Yukiko Kunitomo; Faisal Aslam; Abdulla A Damluji; Nandan S Anavekar; Joseph G Murphy; Sean van Diepen; Gregory W Barsness; Joseph Brennan; Jacob Jentzer Journal: Am J Med Date: 2020-10-28 Impact factor: 4.965